01273 704473

info@novuscomms.com

01273 704473

info@novuscomms.com

Open Orphan #ORPH – New 3 Year Contract with major Pharmaceutical Company January 6, 2020 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a new 3-year contract with a tier 1 German pharmaceutical company which is one of Europe’s top research-driven pharmaceutical companies. The contract guarantees significant annual revenue with work under the contract to commence this month. This contract sees Venn Life Sciences (“Venn”), part of Open Orphan plc, build upon its strong existing relationship with this German pharmaceutical company with a new…

Continue reading

Open Orphan #ORPH – New Contract with SFA Therapeutics December 18, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with SFA Therapeutics, a biopharmaceutical company based in Pennsylvania, USA (“SFA Therapeutics”). This contract sees Venn Life Sciences (“Venn”), part of Open Orphan plc, provide SFA Therapeutics with assistance in the filing of a European Medicines Agency application for Orphan Drug Designation including providing both consulting and regulatory writing services. Open Orphan is delighted to support SFA…

Continue reading

Open Orphan (ORPH) – Early adopters signed for Genomic Health DataBANK November 25, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce it has signed five pharmaceutical and biotechnology companies as early adopters of its Genomic Health DataBANK platform. The platform is expected to be completed and rolled out in Q1 2020. The five companies signed up to the Genomic Health DataBANK platform will ensure the database is ‘fit-for-purpose’ from a pharmaceutical and data analysis perspective ahead of the first patient data upload. This builds…

Continue reading

Open Orphan (ORPH) Contract signed with Carna Bioscience November 18, 2019 – Posted in: Open Orphan (ORPH)

  Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce the signing of a contract with Carna Bioscience (“Carna”) (www.carnabio.com) for a First In Human Clinical pharmacology trial. The contract is expected to deliver significant revenue for the Company over the next twelve  months. Carna is a Japanese company specialising in kinase biology, developing innovative treatments against cancer and immune disorders. This contract sees Venn Life Sciences (“Venn”), part…

Continue reading

Open Orphan (ORPH) to attend Jefferies 2019 London Healthcare Conference November 15, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform, is pleased to announce that the Company will be attending the Jefferies 2019 London Healthcare Conference on 20th-21st November 2019 in London, UK. The conference will be attended by a range of international healthcare executives and institutional investors who will gather to address near and long-term investment opportunities and to discuss the mechanisms driving global healthcare. Open Orphan’s Chief Executive Officer, Cathal Friel, will be in attendance and will…

Continue reading

Open Orphan PLC (ORPH) Signs Preferred Partner Agreement November 11, 2019 – Posted in: Open Orphan (ORPH)

Open Orphan, a European-focussed, rare and orphan drug consulting services platform company, is pleased to announce the signing of a preferred partner agreement between Open Orphan and Ipsen Group (“Ipsen”). The agreement selects Venn Life Sciences (“Venn”), which is part of the Open Orphan group, as the preferred partner for Ipsen’s Data Management and Biostatistics. The preferred vendor structure will last for a 3-year period. This partnership has already delivered substantial revenues for the Open Orphan group…

Continue reading